PP01.48 Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations

Patients with advanced NSCLC without EGFR-activating mutations (EGFRm) have limited treatment options after failure of molecularly targeted therapies or platinum-based chemotherapy (PBC) with or without immunotherapy (IO). HER3-DXd is an antibody drug conjugate consisting of a fully human anti-HER3 mAb attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Here we present updated results, previously presented at ASCO 2022, in patients without tumor EGFRm who progressed after PBC ± IO treatment.